Altavista Wealth Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-3,511
Closed -$252K 140
2017
Q4
$252K Sell
3,511
-111
-3% -$8.43K 0.11% 131
2017
Q3
$293K Sell
3,622
-70
-2% -$5.35K 0.14% 108
2017
Q2
$261K Sell
3,692
-352
-9% -$23.4K 0.13% 117
2017
Q1
$275K Sell
4,044
-567
-12% -$39.9K 0.14% 113
2016
Q4
$330K Sell
4,611
-1,342
-23% -$99.7K 0.18% 91
2016
Q3
$471K Buy
5,953
+305
+5% +$24.8K 0.26% 78
2016
Q2
$471K Buy
5,648
+340
+6% +$30.2K 0.26% 75
2016
Q1
$488K Buy
5,308
+578
+12% +$52.1K 0.28% 73
2015
Q4
$479K Buy
4,730
+1
+0% +$104 0.28% 76
2015
Q3
$464K Sell
4,729
-20
-0.4% -$2.22K 0.31% 79
2015
Q2
$556K Hold
4,749
0.34% 69
2015
Q1
$466K Buy
4,749
+305
+7% +$31K 0.29% 78
2014
Q4
$422K Buy
4,444
+911
+26% +$94.2K 0.26% 80
2014
Q3
$376K Sell
3,533
-2,366
-40% -$232K 0.24% 79
2014
Q2
$489K Sell
5,899
-3,499
-37% -$272K 0.3% 73
2014
Q1
$666K Buy
9,398
+3,555
+61% +$279K 0.41% 71
2013
Q4
$439K Sell
5,843
-2,055
-26% -$143K 0.27% 80
2013
Q3
$497K Hold
7,898
0.32% 76
2013
Q2
$405K Buy
+7,898
New +$412K 0.27% 77

Other funds holding GILD

Altavista Wealth Management's GILD Position: Q1 2018 in Review

Altavista Wealth Management sold out of Gilead Sciences (GILD) in Q1 2018, closing a stake of 3,511 shares — an estimated $252K sold.

Altavista Wealth Management first reported a position in GILD in Q2 2013 and held it in 19 quarters. The position peaked at $666K in Q1 2014. 1,564 funds tracked by Wall St. Rank hold GILD as of Q1 2018.

  • Altavista Wealth Management reported no remaining Gilead Sciences position as of Q1 2018 after selling out during the quarter.
  • Altavista Wealth Management sold 3,511 Gilead Sciences shares in Q1 2018, an estimated $252K.
  • Altavista Wealth Management first reported a position in Gilead Sciences in Q2 2013 and held it in 19 quarters.
  • Altavista Wealth Management's Gilead Sciences position peaked at $666K in Q1 2014.
  • 1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2018.

Based on Altavista Wealth Management's 13F filing for Q1 2018, filed 16 May 2018.